Novo Nordisk (NVO) stock rebounds after Kepler Cheuvreux upgrades to Buy following a 42% stock drop over the past year. Read ...

Novo Nordisk is providing direct-to-patient delivery of Wegovy (semaglutide) through the NovoCare Pharmacy program.

Novo Nordisk stock was dropping on Wednesday after Roche said it had licensed a promising obesity drug in a deal that could ...

Still, Novo is steadfast in its goal to eventually become a leader in the space, the company’s EVP of rare disease, Ludovic ...

Makers of the popular obesity treatments Wegovy and Zepbound are cutting prices for people without insurance. Danish ...

Eli Lilly is offering vials of its obesity drug Zepbound to patients at a discount — but only if they skip their insurance.

Also, Novo Nordisk offers the possibility of viewing the Annual General Meeting via live webcast on Novo Nordisk's website. Please refer to the enclosed notice for the Annual General Meeting for ...

Drug compounders aren’t ready to give up their ability to produce off-brand versions of Novo Nordisk’s weight-loss drug Wegovy and diabetes treatment Ozempic without a fight. An industry group ...

Novo Nordisk shares rallied on Tuesday as a maker of a weight-loss drug alternative confirmed it won’t be selling it for much longer. Hims & Hers Health Inc.’s stock plunged last week when the ...

Investors are scrambling to adjust, after the telehealth specialist Hims & Hers said it would stop selling an alternative to Novo Nordisk's Wegovy and Ozempic weight-loss drugs. Hims stock stood ...

The revenue increase leaders of the fourth quarter were familiar—Eli Lilly (45%) and Novo Nordisk (30% ... drug conjugate drugs brought by the Seattle biotech—played a significant role ...